United States Patent 8,715,664: Claim Scope, Validity Risks, Expiration, and Anti-TNF Patent Landscape

U.S. Patent No. 8,715,664 is a method-of-treatment patent covering the use of human anti-TNF-alpha antibodies to treat erosive polyarthritis and inhibit radiographic joint damage. Its most commercially relevant embodiments encompass adalimumab, marketed as Humira, and golimumab, marketed as Simponi. The patent does not claim the antibodies themselves. It claims administering qualifying antibodies to patients under disease-specific and clinical-outcome limitations.

The patent’s practical value is narrower than the breadth of its language. The claims require erosive polyarthritis, treatment or inhibition of radiographic progression, and, in the broad independent claims, antibody-performance thresholds measured by surface plasmon resonance and an L929 cytotoxicity assay. Claims 14 and 21 are more commercially concrete because they recite adalimumab, biweekly administration, and a dose of about 40 mg.

The patent was issued on May 6, 2014. Its enforceable term was tied to the earliest effective nonprovisional filing date and is no longer a principal U.S. barrier to adalimumab or golimumab competition. The patent remains important for historical litigation analysis, claim-construction work, and assessment of AbbVie’s broader Humira patent strategy.

What does U.S. Patent 8,715,664 protect?

U.S. Patent 8,715,664 protects methods for administering a human anti-TNF-alpha antibody to a patient with erosive polyarthritis associated with a TNF-alpha-mediated disorder. The claimed result is treatment of the disease or inhibition of radiographic progression, measured through the Total Sharp Score, or TSS.

The patent has four principal claim groups:

Claim group	Core subject matter	Commercial significance
Claims 1-7, 15-17	Inhibition of radiographic disease progression using a qualifying human anti-TNF-alpha antibody	Broad functional method claims
Claims 8-13, 18-21	Treatment of erosive polyarthritis with TSS reduction or inhibition	Includes adalimumab, methotrexate, 40 mg, and biweekly dosing
Claims 22-29	Patient identification followed by treatment with a qualifying antibody	Adds a subject-identification step
Claims 30-33	Antibodies defined by specified CDR sequences and permitted substitutions	Sequence-based narrowing claims

The patent’s independent claims are claims 1, 8, 14 and 22. Claim 14 is the most directly aligned with Humira’s rheumatoid arthritis and psoriatic arthritis use:

Administering adalimumab on a biweekly regimen to inhibit radiographic progression in erosive polyarthritis associated with rheumatoid arthritis or psoriatic arthritis, with the patient’s TSS maintained or decreased.

Claim 21 narrows claim 8 to approximately 40 mg. That dose and schedule correspond closely to the established Humira regimen for several inflammatory diseases.

What antibody-performance limitations apply?

Claims 1, 8 and 22 require the antibody to satisfy all of the following:

Parameter	Claimed threshold	Test method
Binding dissociation constant, Kd	1 × 10^-8 M or less	Surface plasmon resonance
Dissociation rate constant, koff	1 × 10^-3 s^-1 or less	Surface plasmon resonance
L929 cytotoxicity IC50	1 × 10^-7 M or less	Standard in vitro L929 assay

These limitations create both technical specificity and litigation exposure. A product may bind TNF-alpha and be clinically effective but fall outside the literal claim if the accused antibody fails one of the stated kinetic or functional thresholds under the relevant assay conditions.

How do the claims cover adalimumab and golimumab?

The patent expressly recites both adalimumab and golimumab in dependent claims.

Adalimumab coverage

Adalimumab is expressly identified in claims 4, 14, 19 and 25. The most commercially important combination is:

adalimumab;
erosive polyarthritis;
rheumatoid arthritis or psoriatic arthritis;
biweekly administration;
radiographic progression inhibition; and
maintenance or reduction of TSS.

Claim 14 does not expressly recite the antibody-binding kinetic thresholds found in claims 1, 8 and 22. That distinction matters. Claim 14 is a standalone claim depending from neither claim 1 nor claim 8. It therefore presents a more direct infringement theory for the specified adalimumab regimen, subject to the claim’s disease and outcome requirements.

Golimumab coverage

Golimumab is recited in claims 2 and 23. The patent does not provide a similarly narrow golimumab claim specifying a 40 mg dose or a particular dosing interval. Golimumab coverage is principally tied to the broader antibody-performance and treatment limitations in claims 1 and 22.

Sequence-defined antibody coverage

Claims 3, 18 and 24 refer to an antibody with:

an LCVR comprising SEQ ID NO: 1; and
an HCVR comprising SEQ ID NO: 2.

Claims 30-33 define related antibodies by CDR1, CDR2 and CDR3 sequences, including limited alanine substitutions and conservative substitutions. These provisions appear directed primarily to the disclosed anti-TNF antibody sequence family rather than to every anti-TNF antibody with equivalent clinical activity.

For adalimumab, the sequence limitations are legally significant because Humira’s antibody sequence is separately protected by foundational composition-of-matter patents and related formulation and manufacturing patents. Patent 8,715,664 adds a treatment-use layer rather than replacing the composition claims.

When did U.S. Patent 8,715,664 expire?

The patent issued on May 6, 2014, from a continuation-type prosecution history associated with an earlier anti-TNF patent family. The enforceable term was governed by the earliest applicable nonprovisional filing date, not by the issue date. The patent’s effective U.S. term ended in the early 2020s and did not extend to the later Humira biosimilar launch period.

The practical conclusion is clear: Patent 8,715,664 is not a current U.S. exclusivity barrier to biosimilar adalimumab or to ordinary commercial use of the claimed anti-TNF treatment methods.

Event	Date or period
Patent issued	May 6, 2014
Patent type	U.S. method-of-treatment patent
Principal products implicated	Humira and Simponi
Term basis	Twenty years from applicable earliest nonprovisional filing date, subject to PTA/PTE rules
Current commercial status	Expired or no longer a meaningful barrier to U.S. anti-TNF competition

The exact expiration calculation should be made from the USPTO patent-term data, including any patent-term adjustment and terminal disclaimer information. A patent-term extension under 35 U.S.C. § 156 would require a qualifying regulatory approval and is not the ordinary basis for extending this type of treatment-method patent.

What is the Orange Book or Purple Book status of Patent 8,715,664?

Patent 8,715,664 is not best analyzed as an Orange Book patent. Humira and Simponi are biologics regulated under the Public Health Service Act, and biosimilar patent information is handled through the Purple Book and the BPCIA patent-exchange process rather than the conventional small-molecule Orange Book listing system.

The relevant regulatory framework is:

Humira: BLA 125057;
Simponi: BLA 125289;
biosimilar pathway: section 351(k) of the Public Health Service Act;
patent exchange: BPCIA section 351(l);
FDA biologic reference-product information: Purple Book.

Patent listing for biologics is more fragmented than the Orange Book system. A patent may be relevant to BPCIA litigation even when it is not presented in an Orange Book-style public listing. The patent’s relevance therefore depends on asserted claims, infringement theories, validity defenses and settlement terms rather than on Orange Book listing status alone.

How strong are the claims of Patent 8,715,664?

The patent has mixed claim strength.

Strengths

The strongest aspects are the commercial specificity and clinical endpoint language in claims 14 and 21. Those claims identify:

adalimumab;
a recognized inflammatory disease;
a biweekly regimen;
approximately 40 mg dosing; and
inhibition of radiographic progression measured by TSS.

These limitations closely track approved and clinically established use patterns. They can make anticipation more difficult if no single prior-art reference discloses the complete combination.

The patent also uses a measurable clinical endpoint. TSS is a recognized radiographic measure in rheumatoid arthritis trials, reducing ambiguity compared with purely subjective treatment language.

Weaknesses

The principal weaknesses are:

Functional overlap with earlier anti-TNF clinical literature.
Rheumatoid arthritis treatment with anti-TNF antibodies, combination therapy with methotrexate, and inhibition of joint damage were extensively studied before the patent’s relevant filing period.
Written-description and enablement pressure.
The broad claims reach any human anti-TNF-alpha antibody satisfying specified kinetic and functional criteria, while the specification may disclose a more limited antibody set. The breadth of the genus relative to the examples can create vulnerability under 35 U.S.C. § 112.
Assay sensitivity.
Kd, koff and L929 IC50 values can vary with antibody format, TNF-alpha preparation, immobilization method, temperature, assay configuration and data analysis. A dispute over assay conditions could become central to infringement and validity.
TSS causation and proof.
A claimant must connect the accused treatment to the claimed radiographic result. Treatment of erosive polyarthritis alone does not necessarily establish that the TSS was maintained or decreased.
Divided infringement risk.
The claims require administration to a patient and, in some cases, identification of a qualifying patient. Manufacturer conduct may not itself constitute direct performance of every method step. Indirect infringement would depend on labeling, instructions, inducement evidence and other facts.
Subject-matter eligibility.
Treatment methods generally fare better under section 101 than diagnostic correlations, but a claim that relies heavily on a natural relationship between TNF inhibition and radiographic improvement may still attract an eligibility challenge if drafted or construed as merely observing a biological result.

Could a biosimilar manufacturer face a Paragraph IV challenge?

Paragraph IV is principally a Hatch-Waxman mechanism for small-molecule drugs, not the standard pathway for biosimilar adalimumab or golimumab. A biosimilar applicant uses the BPCIA process, including patent disclosures, information exchanges, infringement litigation and launch provisions.

For Humira biosimilars, the relevant challenges targeted multiple patent families covering:

antibody composition;
formulations;
high-concentration formulations;
dosing regimens;
manufacturing processes;
treatment methods; and
device or delivery configurations.

Patent 8,715,664 could have been challenged on invalidity and noninfringement grounds during BPCIA litigation. Typical defenses would include:

Defense	Application to Patent 8,715,664
Anticipation	Earlier clinical or patent disclosure of adalimumab treatment, dosing and radiographic outcomes
Obviousness	Combination of known anti-TNF therapy, biweekly dosing, methotrexate and radiographic endpoints
Written description	Breadth of all antibodies meeting the kinetic and L929 thresholds
Enablement	Ability to practice the full antibody and disease scope without undue experimentation
Noninfringement	Failure to meet TSS, disease, dosing, antibody-sequence or assay limitations
Divided infringement	No single actor performs all required treatment steps
Indefiniteness	Meaning of terms such as “about 40 mg,” “treated,” or “radiographic progression inhibited”

After the patent’s expiration, a challenge would have limited commercial value because the patent could no longer block launch. The important litigation period was before or around the first U.S. biosimilar launches.

What patent litigation affected Humira and this patent family?

AbbVie pursued extensive litigation against Humira biosimilar applicants under the BPCIA framework. The disputes involved many patents rather than a single blocking patent. AbbVie and biosimilar applicants, including Amgen and other manufacturers, entered settlements that permitted staggered biosimilar launches.

Humira biosimilars began entering the U.S. market in 2023. The settlements generally preserved AbbVie’s U.S. market position until 2023 while allowing negotiated launch dates for individual competitors. Patent 8,715,664 was part of the broader treatment-method landscape, but the commercial outcome depended on the entire patent portfolio and settlement structure.

The principal litigation lesson is that a method patent of this type rarely determines launch timing alone. A biosimilar applicant evaluates the cumulative risk from composition, formulation, manufacturing and method-of-use patents. An expired method patent may still matter in damages history or claim construction, but it does not preserve portfolio-level exclusivity.

What formulation and manufacturing patents remain relevant?

Patent 8,715,664 does not claim:

a particular Humira formulation;
citrate-free or high-concentration adalimumab;
a prefilled syringe;
an autoinjector;
a manufacturing cell line;
a purification process; or
a specific container-closure system.

Those subjects were addressed through separate patent families. For Humira, the commercially important later portfolio included patents directed to high-concentration formulations and delivery systems. Such patents created greater practical launch risk for biosimilars than the older radiographic-treatment claims because they could affect the marketed presentation even after foundational antibody patents expired.

Manufacturing patents can also create a distinct barrier. A biosimilar manufacturer may avoid literal infringement by using a different cell line, purification process or formulation, but it must still demonstrate analytical similarity, clinical comparability and manufacturing consistency to FDA.

How does Patent 8,715,664 compare with the core Humira patents?

Patent category	Typical protection	Strategic role
Composition of matter	Adalimumab antibody sequence and binding properties	Foundational exclusivity
Treatment method	Anti-TNF treatment of erosive polyarthritis and radiographic progression	Use-specific protection
Formulation	Concentration, excipients, stability and citrate content	Product-presentation protection
Device	Syringe, injector and delivery configuration	Commercial product protection
Manufacturing	Cell culture, purification and process conditions	Process and supply-chain protection

Patent 8,715,664 is weaker than a valid composition-of-matter patent because a competitor can avoid it by changing the indication, dosing method, label, clinical use or factual circumstances of treatment. It is stronger than a generic functional-use patent where the claim directly names adalimumab and the commercially standard 40 mg biweekly regimen.

Its commercial value was therefore portfolio-dependent. It could increase litigation cost and settlement leverage, but it was unlikely to independently support long-term Humira exclusivity once core composition and formulation barriers fell away.

What generic or biosimilar launch risks exist?

For adalimumab, the relevant competitive products are biosimilars rather than conventional generics. The main launch scenarios were:

Interchangeable or non-interchangeable adalimumab biosimilar launch after settlement.
Label carve-outs for patented indications or dosing instructions.
Alternative formulation or device presentation.
Risk-adjusted launch based on remaining formulation and manufacturing patents.
Post-expiration competition without meaningful exposure under Patent 8,715,664.

For golimumab, biosimilar competition has been less advanced than for adalimumab. The patent’s golimumab claims are narrower in commercial detail and depend more heavily on proving that the product satisfies the specified antibody-performance limitations and treatment outcomes.

What is the geographic scope of Patent 8,715,664?

The patent is a U.S. right. It has no direct force in Europe, Canada, Japan or other jurisdictions. Parallel patent families may exist abroad, but each jurisdiction applies its own rules on:

patentable subject matter;
medical-treatment claims;
claim construction;
supplementary protection;
biosimilar litigation; and
patent-term adjustment.

A U.S. expiration does not establish expiration of corresponding foreign rights. Commercial freedom-to-operate analysis for adalimumab or golimumab must therefore be conducted jurisdiction by jurisdiction.

Key Takeaways

Patent 8,715,664 claims anti-TNF treatment methods, not the adalimumab or golimumab molecules themselves.
The patent’s core subject is treatment of erosive polyarthritis and inhibition of radiographic progression measured by TSS.
Claims 14 and 21 are the most commercially specific because they recite adalimumab, biweekly administration and approximately 40 mg dosing.
Claims 1, 8 and 22 impose Kd, koff and L929 assay thresholds that create technical infringement and proof issues.
The patent is no longer a meaningful U.S. exclusivity barrier to Humira biosimilar entry.
Biologic competition is governed by the BPCIA and Purple Book framework, not ordinary Orange Book Paragraph IV procedures.
The patent’s strongest litigation value was historical and portfolio-based. Composition, formulation, device and manufacturing patents were more important to overall Humira launch control.
The patent has jurisdiction-specific relevance and cannot be treated as a global anti-TNF right.

FAQs

Does U.S. Patent 8,715,664 cover Humira itself?

No. It covers specified methods of using adalimumab and other qualifying human anti-TNF-alpha antibodies. Humira’s molecule, formulations and delivery systems were covered by separate patent families.

Does the patent require methotrexate?

No. Methotrexate appears in dependent claims 7, 13 and 29. The independent treatment claims do not require concomitant methotrexate.

Does every adalimumab injection infringe the patent claims?

No. Infringement would require satisfaction of the applicable disease, dosing, administration and radiographic-outcome limitations. Ordinary administration of adalimumab does not automatically establish infringement.

Is TSS required for every claim?

No. Claims 1 and 14 expressly address maintenance or reduction of TSS. Claim 8 requires a statistically significant reduction or inhibition in joint damage measured by TSS. Claims 22 and related dependent claims do not all repeat the same radiographic limitation.

Are Humira biosimilars generic drugs under the Hatch-Waxman Act?

No. Humira biosimilars are biological products licensed under section 351(k) of the Public Health Service Act. Their patent disputes proceed primarily under the BPCIA framework.

Could a foreign patent corresponding to Patent 8,715,664 still be active?

Yes. U.S. expiration does not determine the status of related patents in Europe or other jurisdictions. Foreign rights require separate patent-family and term analysis.

References

U.S. Patent No. 8,715,664. (2014). Methods for treating inflammatory disorders using anti-TNF antibodies. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Humira (adalimumab) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262(l).
Patent Term Adjustment Act, 35 U.S.C. § 154(b).
Patent Term Extension Act, 35 U.S.C. § 156.
U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar products. FDA.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,715,664	2026-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,715,664	2026-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,715,664	2026-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	8,715,664	2026-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	8,715,664	2026-05-16
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	March 9, 2016	8,715,664	2026-05-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
Argentina	040603	⤷ Start Trial
Argentina	045710	⤷ Start Trial
Argentina	077474	⤷ Start Trial
Argentina	077573	⤷ Start Trial
Argentina	098173	⤷ Start Trial
Austria	E517632	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 8,715,664

Summary for Patent: 8,715,664